Published 19 January 2021
Background - To investigate the effect of frailty on short-term postoperative outcomes in patients with prostate cancer treated with radical prostatectomy (RP).
Methods - Within the National Inpatient Sample database, we identified 91,618 RP patients treated between 2008 and 2015. The Johns Hopkins Adjusted Clinical Groups frailty-defining indicator was applied, and we examined the rates of frailty over time, as well as its effect on overall complications, major complications, nonhome-based discharge, length of stay (LOS), and total hospital charges (THCs). Time trends and multivariable logistic, Poisson and linear regression models were applied.
Results - Overall, 12,185 (13.3%) patients were frail. Rates of frail patients increased over time (from 10.3 to 18.2%; p 0.001). Frail patients had higher rates of overall complications (16.6 vs. 8.6%), major complications (4.9 vs. 2.6%), nonhome-based discharge (5.9 vs. 5%), longer LOS (2 vs. 1), and higher
E-Mail
The most promising vaccine against the coronavirus to date is also an example of the long-term value of curiosity-driven basic research and its funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation). The so-called mRNA vaccine platform, which the Mainz-based company BioNTech uses in its Covid-19 vaccine developed jointly with the US pharmaceutical company Pfizer, can be traced back to preliminary work carried out from 2006 to 2008 in a project within a DFG-funded Collaborative Research Centre (CRC) on cancer research at the Johannes Gutenberg University Mainz. This in turn was also tied to previous DFG-funded research.
The project was led by the later founder and current CEO of BioNTech, Professor Dr. U?ur ?ahin, whose name and person are closely associated with the development of the BNT162b2 vaccine, which will be deployed immediately following its approval in the United Kingdom and its anticipated approval in the USA and the EU. In addition to